用达卡巴嗪、长春地辛和顺铂治疗转移性恶性黑色素瘤。
Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
作者信息
Pectasides D, Yianniotis H, Alevizakos N, Bafaloukos D, Barbounis V, Varthalitis J, Dimitriadis M, Athanassiou A
机构信息
Department of Medical Oncology, Metaxas Memorial Cancer Hospital, Piraeus, Greece.
出版信息
Br J Cancer. 1989 Oct;60(4):627-9. doi: 10.1038/bjc.1989.327.
Abstract
Twenty-seven patients with disseminated malignant melanoma were treated monthly with cisplatin (CDDP) 120 mg m-2 on day 1, vindesine (VDS) 3 mg m-2 on day 2 and dacarbazine (DTIC) 250 mg m-2 on days 2-6. None of them had received prior chemotherapy. All patients are evaluable for response and toxicity. There were five (19%) complete (CR) and seven (26%) partial (PR) responses for a total response rate of 45%. We conclude that the combination of DTIC, VDS and CDDP is capable of producing a relatively high rate of response in patients with advanced metastatic malignant melanoma, but responses are short.
摘要
27例播散性恶性黑色素瘤患者接受如下治疗：第1天给予顺铂（CDDP）120 mg/m²，第2天给予长春地辛（VDS）3 mg/m²，第2 - 6天给予达卡巴嗪（DTIC）250 mg/m²，每月1次。所有患者此前均未接受过化疗。所有患者均可评估疗效及毒性。有5例（19%）完全缓解（CR），7例（26%）部分缓解（PR），总缓解率为45%。我们得出结论，DTIC、VDS和CDDP联合应用能够使晚期转移性恶性黑色素瘤患者产生相对较高的缓解率，但缓解持续时间较短。
相似文献
1
Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.用达卡巴嗪、长春地辛和顺铂治疗转移性恶性黑色素瘤。
Br J Cancer. 1989 Oct;60(4):627-9. doi: 10.1038/bjc.1989.327.
2
Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial.达卡巴嗪-长春地辛与达卡巴嗪-长春地辛-顺铂治疗播散性恶性黑色素瘤的对比：一项随机III期试验
Eur J Cancer. 1998 Aug;34(9):1368-74. doi: 10.1016/s0959-8049(98)00068-9.
3
Phase II study of bleomycin, actinomycin D, DTIC and vindesine in disseminated malignant melanoma.博来霉素、放线菌素D、达卡巴嗪和长春地辛治疗播散性恶性黑色素瘤的II期研究
Eur J Cancer Clin Oncol. 1986 Jul;22(7):879-81. doi: 10.1016/0277-5379(86)90377-9.
4
Dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A phase I-II trial.达卡巴嗪-长春地辛-顺铂治疗播散性恶性黑色素瘤：一项I-II期试验
Am J Clin Oncol. 1990 Jun;13(3):214-7. doi: 10.1097/00000421-199006000-00007.
5
A feasibility study using polychemotherapy (cisplatin + vindesine + dacarbazine) plus interferon-alpha or monochemotherapy with dacarbazine plus interferon-alpha in metastatic melanoma.一项关于转移性黑色素瘤采用多药化疗（顺铂 + 长春地辛 + 达卡巴嗪）联合α干扰素或达卡巴嗪单药化疗联合α干扰素的可行性研究。
Tumori. 2001 Jul-Aug;87(4):219-22. doi: 10.1177/030089160108700402.
6
Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma. A Phase II Study of the EORTC Malignant Melanoma Cooperative Group.顺铂、长春地辛和达卡巴嗪联合治疗晚期恶性黑色素瘤。欧洲癌症研究与治疗组织恶性黑色素瘤协作组的一项II期研究。
Cancer. 1988 Sep 15;62(6):1061-5. doi: 10.1002/1097-0142(19880915)62:6<1061::aid-cncr2820620607>3.0.co;2-x.
7
A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma.一项高剂量顺铂和达卡巴嗪的II期试验。高剂量基于顺铂的疗法对转移性黑色素瘤无效。
Cancer. 1991 Sep 15;68(6):1230-7. doi: 10.1002/1097-0142(19910915)68:6<1230::aid-cncr2820680608>3.0.co;2-q.
8
Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma).顺铂、达卡巴嗪、长春地辛、皮下注射白细胞介素-2、干扰素α2a和他莫昔芬综合治疗转移性黑色素瘤的多机构II期随机试验。BREMIM（黑色素瘤生物反应调节剂）。
Melanoma Res. 1999 Oct;9(5):503-9. doi: 10.1097/00008390-199910000-00010.
9
Phase II study of vindesine and dacarbazine with or without non-specific stimulation of the immune system in patients with metastatic melanoma.长春地辛与达卡巴嗪联合或不联合非特异性免疫系统刺激用于转移性黑色素瘤患者的II期研究。
Eur J Cancer. 1993;29A(5):708-11. doi: 10.1016/s0959-8049(05)80351-x.
10
Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma.达卡巴嗪、顺铂、福莫司汀和他莫昔芬联合治疗转移性恶性黑色素瘤。
Melanoma Res. 1998 Apr;8(2):170-4. doi: 10.1097/00008390-199804000-00012.
引用本文的文献
1
Reprogramming of T cell-derived small extracellular vesicles using IL2 surface engineering induces potent anti-cancer effects through miRNA delivery.通过 IL2 表面工程对 T 细胞衍生的小细胞外囊泡进行重编程，通过 miRNA 递送来诱导有效的抗癌作用。
J Extracell Vesicles. 2022 Dec;11(12):e12287. doi: 10.1002/jev2.12287.
2
Epigenetic modulation and apoptotic induction by a novel imidazo-benzamide derivative in human lung adenocarcinoma cells.新型咪唑并苯甲酰胺衍生物对人肺腺癌细胞的表观遗传调控和凋亡诱导作用。
Daru. 2021 Dec;29(2):377-387. doi: 10.1007/s40199-021-00419-3. Epub 2021 Oct 12.
3
Design, Synthesis and Anticancer Activity of New Polycyclic: Imidazole, Thiazine, Oxathiine, Pyrrolo-Quinoxaline and Thienotriazolopyrimidine Derivatives.新型多环：咪唑、噻嗪、氧硫杂环戊烷、吡咯并喹喔啉和噻吩并三氮唑嘧啶衍生物的设计、合成与抗癌活性。
Molecules. 2021 Apr 2;26(7):2031. doi: 10.3390/molecules26072031.
4
Synthesis of Imidazole-Based Medicinal Molecules Utilizing the van Leusen Imidazole Synthesis.利用范鲁森咪唑合成法合成基于咪唑的药用分子。
Pharmaceuticals (Basel). 2020 Mar 3;13(3):37. doi: 10.3390/ph13030037.
5
Imidazoles as potential anticancer agents.咪唑类作为潜在的抗癌药物。
Medchemcomm. 2017 Apr 13;8(9):1742-1773. doi: 10.1039/c7md00067g. eCollection 2017 Sep 1.
6
Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway.胰岛素通过激活PI3K/Akt信号通路诱导黑色素瘤产生耐药性。
Drug Des Devel Ther. 2014 Feb 17;8:255-62. doi: 10.2147/DDDT.S53568. eCollection 2014.
7
[Therapy of malignant melanoma at the stage of distant metastasis].[远处转移阶段恶性黑色素瘤的治疗]
Hautarzt. 2004 Feb;55(2):195-213. doi: 10.1007/s00105-003-0684-1.
8
Association between chemotherapy response and rate of disease progression in disseminated melanoma.播散性黑色素瘤化疗反应与疾病进展速率之间的关联
Br J Cancer. 1991 Jan;63(1):154-6. doi: 10.1038/bjc.1991.32.
本文引用的文献
1
DTIC therapy in metastatic malignant melanoma: a simplified dose schedule.达卡巴嗪治疗转移性恶性黑色素瘤：一种简化的剂量方案。
Cancer Treat Rep. 1980 Oct-Nov;64(10-11):1123-6.
2
Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A).二甲基三氮烯咪唑甲酰胺及联合疗法治疗黑色素瘤。IV. 化疗完全缓解后的远期结果（中央肿瘤学组方案7130、7131和7131A）
Cancer. 1984 Mar 15;53(6):1299-305. doi: 10.1002/1097-0142(19840315)53:6<1299::aid-cncr2820530613>3.0.co;2-4.
3
Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma.长春花碱、博来霉素和顺二氯二氨铂对比达卡巴嗪治疗恶性黑色素瘤的随机III期试验
J Clin Oncol. 1984 Mar;2(3):164-8. doi: 10.1200/JCO.1984.2.3.164.
4
Treatment of metastatic malignant melanoma with vinblastine, bleomycin by infusion and cisplatin.用长春碱、博来霉素静脉输注和顺铂治疗转移性恶性黑色素瘤。
Cancer. 1983 Dec 15;52(12):2220-2. doi: 10.1002/1097-0142(19831215)52:12<2220::aid-cncr2820521208>3.0.co;2-p.
5
Phase II study of the combination of vinblastine, bleomycin, and cisplatin in advanced malignant melanoma.长春花碱、博来霉素和顺铂联合治疗晚期恶性黑色素瘤的II期研究。
Cancer Treat Rep. 1982 Mar;66(3):567-9.
6
Vinblastine, infusion, bleomycin, and cis-dichlorodiammine-platinum chemotherapy in metastatic melanoma.长春花碱、静脉输注、博来霉素和顺二氯二氨铂治疗转移性黑色素瘤。
Cancer. 1981 Sep 15;48(6):1290-4. doi: 10.1002/1097-0142(19810915)48:6<1290::aid-cncr2820480605>3.0.co;2-1.
7
Prognostic correlations and response to treatment in advanced metastatic malignant melanoma.晚期转移性恶性黑色素瘤的预后相关性及对治疗的反应
Cancer Res. 1974 Aug;34(8):1995-2004.
8
Treatment of metastatic malignant melanoma with dacarbazine and cisplatin.用达卡巴嗪和顺铂治疗转移性恶性黑色素瘤。
Cancer Treat Rep. 1987 Sep;71(9):877-8.
9
10
DTIC (NSC-45388) studies in the southwest oncology group.西南肿瘤协作组中达卡巴嗪（NSC - 45388）的研究
Cancer Treat Rep. 1976 Feb;60(2):189-92.
Zotero 插件